A bioprocessing conference and exhibition focused on advancing biopharmaceutical development and manufacturing. Across four ...

Latin America will need to overhaul how it budgets and finances healthcare if it is to strengthen health systems by 2026 and ...

Despite the US Food and Drug Administration’s (FDA) acceptance of Inovio’s Biologics License Application (BLA) for INO-3107 for review as a potential treatment for adults with recurrent respiratory ...

Biocon Biologics, a fully integrated global biosimilars company and subsidiary of India’s Biocon Ltd, announced that it has ...

Enhertu (trastuzumab deruxtecan) has now been approved in China for the treatment of adult patients with unresectable or ...

This month, Samsung Bioepis announced the European launch of Obodence (60 mg pre-filled syringe) and Xbryk (120 mg vial), ...

The age-related macular degeneration (AMD) market in the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK ...

The inauguration of Japanese drug major Takeda's new, state-of-the-art filling line at its Neuchâtel, Switzerland, production ...

Indian drugmaker Biocon has announced the signing of an out-licensing agreement with Ajanta Pharma to market its vertically ...

As many people consider lifestyle changes at the start of the year, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is urging the public to make sure any weight-loss medicines they ...

Chinese biotech Hutchmed today announces that the New Drug Application (NDA) for fanregratinib (HMPL-453) for the treatment of adult patients with advanced, metastatic or unresectable intrahepatic ...

Against the backdrop of a turbulent year marked by both breakthrough and setbacks, the biopharmaceutical industry is entering ...